2020
Formation and function of resident memory t cells in renal allografts
Daya K, Zhao D, Tieu R, Rammal R, Oberbarnscheidt M, Lakkis F. Formation and function of resident memory t cells in renal allografts. The Journal Of Immunology 2020, 204: 161.24-161.24. DOI: 10.4049/jimmunol.204.supp.161.24.Peer-Reviewed Original ResearchOT-IT cellsEndogenous T-cell populationMouse kidney transplant modelOT-I T cellsResident memory T cellsMemory T cellsT cell populationsPreserved kidney functionKidney transplant modelTRM cellsAdoptive transferB6 recipientsTeff cellsChronic rejectionKidney allograftsRe-transplantationRenal allograftsNo significant differenceGraft histologyKidney graftsTransplantation modelBone marrowALLO groupKidney function
2019
Persistent acidosis after reperfusion—A prognostic indicator of increased 30‐day and in‐hospital postoperative mortality in liver transplant recipients
Kim S, DeMaria S, Li J, Lin H, Smith N, Wax D, Hill B, So A, Tabrizian P, Florman S, Feierman D, Zerillo J. Persistent acidosis after reperfusion—A prognostic indicator of increased 30‐day and in‐hospital postoperative mortality in liver transplant recipients. Clinical Transplantation 2019, 33: e13473. PMID: 30597632, DOI: 10.1111/ctr.13473.Peer-Reviewed Original ResearchConceptsRe-transplantation rateRe-transplantationTransplant recipientsLiver transplantationPersistent acidosisIn-hospital postoperative mortalityIn-hospital increaseCorrection of acidosisProgressive lactic acidosisLiver transplant recipientsTotal hospital LOSHepatic artery anastomosisIn-Hospital MortalityPropensity score matchingPostoperative mortalityPostoperative outcomesAdult patientsHospital LOSICU LOSLactic acidosisMortality rate differencesMedian LOSPrimary outcomeArtery anastomosisSecondary outcomes
2012
A decade of experience with a single dose of rabbit antithymocyte globulin or alemtuzumab pretreatment for intestinal and multivisceral transplantation.
Abu-Elmagd K, Costa G, Bond G, Soltys K, Martin L, Koritsky D, Cunha-Melo J, Sogawa H, Irish W, Tzakis A, Mazariegos G. A decade of experience with a single dose of rabbit antithymocyte globulin or alemtuzumab pretreatment for intestinal and multivisceral transplantation. Clinical Transplants 2012, 155-66. PMID: 23721018.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlemtuzumabAnimalsAntibodies, Monoclonal, HumanizedAntilymphocyte SerumAntineoplastic AgentsFemaleGraft RejectionGraft SurvivalGraft vs Host DiseaseHumansImmunosuppressive AgentsIncidenceInfectionsIntestinesMaleMiddle AgedMorbidityPancreas TransplantationRabbitsStomachTransplantation, HomologousYoung AdultConceptsDose of rabbit antithymocyte globulinDe novo malignanciesRabbit antithymocyte globulinTacrolimus trough levelsLong-term immunosuppressionRe-transplantation rateLife-threatening infectionsLong-term survivalAntithymocyte globulinTacrolimus monotherapyAdrenal insufficiencyAllograft acceptanceRecipient pretreatmentTrough levelsImmunosuppressive strategiesSteroid-freeGraft lossSingle-doseAcute/chronic rejectionRe-transplantationGraft survivalMultivisceral transplantationSingle doseSerum sicknessAlemtuzumab pretreatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply